BSD Medical Announces BSD-2000 Marketing Approval Submission to Taiwan Food and Drug Administration by Linden Bioscience

  BSD Medical Announces BSD-2000 Marketing Approval Submission to Taiwan Food
  and Drug Administration by Linden Bioscience

Business Wire

SALT LAKE CITY -- May 13, 2013

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a
leading provider of medical systems that utilize heat therapy to treat cancer,
announced today that its exclusive Taiwan distributor Linden Bioscience Co.,
Ltd. (Linden), has submitted its BSD-2000 marketing approval application for
the BSD-2000 Hyperthermia System (BSD-2000) to the Taiwan Food and Drug
Administration (TFDA). The TFDA approval of the BSD-2000 could occur as early
as November 2013.

“Since signing our exclusive distributor agreement with BSD, Linden has had
ongoing and very productive meetings with the TFDA,” stated Mr. Tainang Huang,
President of Linden. “We have filed the BSD-2000 marketing application with
the TFDA, and we are working closely with the TFDA to obtain an expedited
approval for marketing the BSD-2000 in Taiwan. We have also met with many
prominent Taiwan physicians from several hospitals, including the very
influential and largest hospital system in Taiwan, Chang Gung Memorial. As a
result of our extensive efforts to introduce the BSD-2000 in Taiwan, we have
been invited to present on the BSD-2000 at an international symposium on
hyperthermia in Taipei, which will be held in November 2013 at Wan Fan
Hospital, Taipei Medical University. We are excited about the interest
expressed in the BSD-2000 in Taiwan.”

About the BSD Hyperthermia Systems

The BSD-2000 – developed and patented exclusively by BSD – delivers localized
therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The
BSD-2000 creates a central focusing of energy that can be electronically
focused to target the shape, size and location of the tumor, thus providing
dynamic control of the heating delivered to the tumor region. The BSD-2000 has
Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and
Drug Administration (FDA) for use in conjunction with radiation therapy for
the treatment of cervical cancer patients who are ineligible for chemotherapy.
The BSD-2000 also has CE (Conformité Européenne) Marking approval for the
commercial sale in Europe. CE Marking approval is also recognized in many
countries outside of the EU.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy, which is delivered
using focused radiofrequency (RF) and microwave energy. BSD’s product lines
include both hyperthermia and ablation treatment systems. BSD’s hyperthermia
cancer treatment systems, which have been in use for several years in the
United States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at
www.BSDMedical.com.

This press release may be deemed to contain forward-looking statements, which
are subject to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, including the expected use of proceeds relating to the
recently completed offering. Readers are cautioned that these forward-looking
statements are only predictions and may differ materially from actual future
events or results due to a variety of factors, including, among other things,
the demand for the Company’s products, the ability of the Company to produce
the products to meet the demand, global economic conditions and uncertainties
in the geopolitical environment and other risk factors set forth in the
Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking
statements in this release are based on limited information currently
available to the Company, which is subject to change, and the Company will not
necessarily update the information.

Contact:

BSD Medical Corporation
William Barth, 801-972-5555
fax: 801-972-5930
investor@bsdmc.com